This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Teneligliptin
DrugBank Accession Number
DB11950
Background

Teneligliptin has been investigated for the treatment of Type 2 Diabetes Mellitus.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 426.578
Monoisotopic: 426.220180302
Chemical Formula
C22H30N6OS
Synonyms
  • Teneligliptin
External IDs
  • MP-513

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Teneligliptin.
AcebutololThe therapeutic efficacy of Teneligliptin can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Teneligliptin can be increased when used in combination with Acetazolamide.
AcetohexamideTeneligliptin may increase the hypoglycemic activities of Acetohexamide.
Acetyl sulfisoxazoleThe therapeutic efficacy of Teneligliptin can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Teneligliptin.
AlbiglutideThe risk or severity of hypoglycemia can be increased when Albiglutide is combined with Teneligliptin.
AlclometasoneThe risk or severity of hyperglycemia can be increased when Alclometasone is combined with Teneligliptin.
AlogliptinThe risk or severity of angioedema can be increased when Alogliptin is combined with Teneligliptin.
AlteplaseThe risk or severity of angioedema can be increased when Alteplase is combined with Teneligliptin.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid amides
Alternative Parents
N-arylpiperazines / Phenylpyrazoles / Dialkylarylamines / Pyrrolidinecarboxamides / N-alkylpiperazines / Benzene and substituted derivatives / Heteroaromatic compounds / Tertiary carboxylic acid amides / Thiazolidines / Trialkylamines
show 7 more
Substituents
1,4-diazinane / Alpha-amino acid amide / Amine / Aromatic heteromonocyclic compound / Azacycle / Azole / Benzenoid / Carbonyl group / Carboxamide group / Dialkylarylamine
show 26 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
28ZHI4CF9C
CAS number
760937-92-6
InChI Key
WGRQANOPCQRCME-PMACEKPBSA-N
InChI
InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1
IUPAC Name
1-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-4-[(3S,5S)-5-(1,3-thiazolidine-3-carbonyl)pyrrolidin-3-yl]piperazine
SMILES
[H][C@]1(CN[C@@]([H])(C1)C(=O)N1CCSC1)N1CCN(CC1)C1=CC(C)=NN1C1=CC=CC=C1

References

General References
  1. FDA Thailand Product Information: Tenelia (teneligliptin) oral tablets [Link]
PubChem Compound
11949652
PubChem Substance
347828276
ChemSpider
10123963
BindingDB
50391565
ChEBI
136042
ChEMBL
CHEMBL2147777
ZINC
ZINC000036520254
PDBe Ligand
M51
Wikipedia
Teneligliptin
PDB Entries
3vjk

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentType 2 Diabetes Mellitus4
4RecruitingTreatmentType 2 Diabetes Mellitus1
4Unknown StatusTreatmentType 2 Diabetes Mellitus1
3CompletedTreatmentType 2 Diabetes Mellitus13
2CompletedTreatmentType 2 Diabetes Mellitus2
1CompletedOtherDiabetes Mellitus1
1CompletedOtherHealthy Subjects (HS)2
1CompletedTreatmentDiabetes Mellitus1
1CompletedTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingNot AvailableType 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, coatedOral20 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.4 mg/mLALOGPS
logP1.69ALOGPS
logP1.42ChemAxon
logS-2.5ALOGPS
pKa (Strongest Basic)9.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area56.64 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity121.78 m3·mol-1ChemAxon
Polarizability46.91 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 21:03 / Updated at February 21, 2021 18:53